News about Drug Discovery & Development

Roche Deploys Contivue Manufacturing Platform with CE Mark for nAMD Continuous Drug Delivery

Roche has received CE marking in the European Union for Contivue, its innovative Port Delivery Platform for administering Susvimo in the treatment of neovascular (wet) age-related macular degeneration (nAMD).

Drug Discovery & Development | 04/09/2025 | By Darshana |  350

Nanyang Biologics, NVIDIA, HPE and Equinix Collaborate to Build AI Drug Discovery Platform

Fischer Medical Ventures’ associate company, Nanyang Biologics (NYB), has entered into a strategic collaboration with global technology leaders NVIDIA, Hewlett Packard Enterprise (HPE), and Equinix to build VECURA – an AI-powered drug discovery platform.

Drug Discovery & Development | 03/09/2025 | By Dineshwori |  460

Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK

Piramal Pharma Solutions leveraged its CDMO expertise to help George Medicines develop WIDAPLIK, the first and only FDA-approved triple combination therapy for hypertension, combining telmisartan, amlodipine, and indapamide to effectively lower blood pressure.

Drug Discovery & Development | 01/09/2025 | By Mrinmoy Dey |  287

US FDA Accepts Gadoquatrane for Review: Bayer

Bayer has submitted New Drug Application (NDA) for low dose contrast agent gadoquatrane to seek approval for contrast-enhanced Magnetic Resonance Imaging (MRI) of the Central Nervous System (CNS) and other body regions for adults and paediatric patients including neonates.

Drug Discovery & Development | 27/08/2025 | By Dineshwori |  285

Gland Pharma Secures USFDA Approval for Ready-to-Use Vasopressin Injection

The product is bioequivalent and therapeutically equivalent to the reference drug Vasostrict. Vasopressin is indicated for adults with vasodilatory shock who remain hypotensive despite adequate fluid resuscitation and catecholamine support.

Drug Discovery & Development | 27/08/2025 | By Darshana |  292

Abbott Introduces FreeStyle Libre 2 Plus: Continuous Glucose Monitoring Without Fingersticks

Abbott, a global healthcare leader, has launched the FreeStyle Libre 2 Plus sensor in India, a device that delivers automatic glucose readings every minute directly to a user’s smartphone. The innovation aims to provide people living with diabetes greater confidence, precision, and ease in managing their condition.

Drug Discovery & Development | 22/08/2025 | By Darshana |  754

Stealth BioTherapeutics' Elamipretide NDA Resubmission Accepted for Review by US FDA

Stealth BioTherapeutics has announced that the US FDA has accepted for review its resubmitted New Drug Application for elamipretide to treat Barth syndrome, with a planned goal date of September 26, 2025.

Drug Discovery & Development | 22/08/2025 | By Mrinmoy Dey |  346

Thermo Fisher to Boost India's Biopharma Manufacturing with New Genome Valley Facilities

Thermo Fisher Scientific has announced major investments to strengthen India’s biopharma infrastructure, unveiling plans to establish two state-of-the-art facilities in Hyderabad’s Genome Valley by the end of 2025. The announcement was made during the Biopharma Conclave 2025, where company leaders engaged with government, industry, and academia.

Drug Discovery & Development | 21/08/2025 | By Darshana |  960

MedImpact to Launch Affordable Unbranded Biosimilar Ustekinumab-aekn in 2026

With specialty drug costs rising and many pharmacies closing, MedImpact’s strategy introduces a new sourcing model that provides pharmacies with access to lower prices while giving payers more flexibility and control over healthcare expenses. Importantly, this approach will extend beyond MedImpact’s own clients, offering broader industry-wide benefits.

Drug Discovery & Development | 20/08/2025 | By Darshana |  437

Gland Pharma Secures USFDA Approval for Norepinephrine Bitartrate in 5 Percent Dextrose Injection Bags

Gland Pharma Ltd. has received USFDA approval for its generic Norepinephrine Bitartrate in 5 percent Dextrose Injection, securing First-to-File status with 180 days of exclusivity in the US market.

Drug Discovery & Development | 16/08/2025 | By Mrinmoy Dey |  373